Nick L Occleston Selected Research

human TGFB3 protein

9/2011	Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring.
9/2010	Effects of avotermin (transforming growth factor β3) in a clinically relevant pig model of long, full-thickness incisional wounds.
1/2010	Therapies with emerging evidence of efficacy: avotermin for the improvement of scarring.
8/2009	Avotermin for the improvement of scar appearance: a new pharmaceutical in a new therapeutic area.
4/2009	Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies.
11/2008	New therapeutics for the prevention and reduction of scarring.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nick L Occleston Research Topics

Disease

7	Cicatrix (Scar) 09/2011 - 01/2008
3	Wounds and Injuries (Trauma) 09/2010 - 04/2009
1	Erythema 04/2009

Drug/Important Bio-Agent (IBA)

6	human TGFB3 proteinIBA 09/2011 - 11/2008
3	Transforming Growth Factor beta (TGF-beta)IBA 09/2011 - 01/2008
3	Pharmaceutical PreparationsIBA 08/2009 - 01/2008
2	Prescription DrugsIBA 01/2010 - 01/2008
2	Transforming Growth Factor beta3 (TGF beta 3)IBA 08/2009 - 04/2009
1	Transforming Growth Factors (Transforming Growth Factor)IBA 09/2010
1	CytokinesIBA 01/2010
1	CollagenIBA 04/2009

Therapy/Procedure

4	Therapeutics 09/2011 - 11/2008
1	Reoperation 01/2010